Page header

Opinion of the Transparency Council – telmisartan + amlodipine besylate + hydrochlorothiazide

At its meeting on 13 May 2025, the Transparency Council adopted opinion No. 83/2025 on the inclusion of medicinal products containing the active substances telmisartan + amlodipine besylate + hydrochlorothiazide in the reimbursement scheme for indications for use or dosage or method of administration other than those specified in the Summary of Product Characteristics, i.e. hypertension

 

Publication of the opinion >>